Search

Your search keyword '"Bewley, Anthony"' showing total 489 results
Start Over Author "Bewley, Anthony"
489 results on '"Bewley, Anthony"'

5. A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis

Author

Abraham, Thamir, Ali, Muhmad, August, Suzannah, Baudry, David, Becher, Gabrielle, Bewley, Anthony, Brown, Victoria, Cornelius, Victoria, Ghaffar, Sharizan, Ingram, John, Kavakleiva, Svetlana, Kelly, Susan, Khorshid, Mohsen, Lachmann, Helen, Ladoyanni, Effie, McAteer, Helen, McKenna, John, Meynell, Freya, Patel, Prakash, Pink, Andrew, Powell, Kingsley, Pushparajah, Angela, Sinclair, Catriona, Wachsmuth, Rachel, Hernandez-Cordero, Ariana, Thomas, Laurent, Smail, Alice, Lim, Zhao Qin, Saklatvala, Jake R., Chung, Raymond, Curtis, Charles J., Baum, Patrick, Visvanathan, Sudha, Burden, A. David, Cooper, Hywel L., Dunnill, Giles, Griffiths, Christopher E.M., Levell, Nick J., Parslew, Richard, Reynolds, Nick J., Wahie, Shyamal, Warren, Richard B., Wright, Andrew, Simpson, Michael, Hveem, Kristian, Barker, Jonathan N., Dand, Nick, Løset, Mari, Smith, Catherine H., and Capon, Francesca

Published
2024
Full Text
View/download PDF

9. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics

Author

Ahmed, Shehnaz, Alabas, Oras, Barker, Jonathan, Becher, Gabrielle, Bewley, Anthony, Evans, Ian, Hampton, Philip, Kirby, Brian, Kleyn, Elise, Laws, Philip, Lawson, Linda, Mackenzie, Teena, McElhone, Kathleen, McPherson, Tess, Morrison, Simon, Owen, Caroline, Pearson, Eleanor, Rashid, Amir, Reynolds, Nick, Strangfeld, Anja, Walton, Shernaz, Yiu, Zenas, Gupta, Girish, Strangfeld (chair), Anja, Weller, Richard, Zietemann, Vera, Aldoori, Nadia, Ali, Mahmud, Al-Rusan, Ahmed, Angit, Caroline, Anstey, Alex, Antony, Fiona, Archer, Charles, August, Suzanna, Balasubramaniam, Periasamy, Baudry, David, Baxter, Kay, Bonsall, Alexandra, Brown, Sara, Brown, Victoria, Burden, David, Burova, Ekaterina, Butt, Aamir, Caswell, Mel, Chapman, Anna, Cliff, Sandeep, Costache, Mihaela, Darne, Sharmela, DeGiovanni, Claudia, Desai, Trupti, Diba, Victoria, Domanne, Eva, Duckworth, Michael, Dymond, Harvey, Fahy, Caoimhe, Farwer, Susanne, Ferguson, Leila, Gkini, Maria-Angeliki, Godwin, Alison, Goulding, Jon, Hammonds, Fiona, Haque, Shaheen, Higgins, Caroline, Hood, Sue, Joseph, Teresa, Johnson, Sarah, Kalavala, Manju, Khorshid, Mohsen, Labinoti, Liberta, Lamb, Ruth, Lawson, Nicole, Layton, Alison, Lees, Tara, Levell, Nick, Lewis, Helen, Lovell, Chris, Lyon, Calum, McAteer, Helen, McBride, Sandy, McCormack, Sally, McKenna, Kevin, Mellor, Serap, Meredith, Fiona, Murphy, Ruth, Norris, Paul, Parslew, Richard, Perera, Gay, Ponnambath, Nabil, Popli, Urvi, Powell, James, Ramesh, Raakhee, Ramsay, Helen, Ranasinghe, Aruni, Reeken, Saskia, Rose, Rebecca, Rotarescu, Rada, Salvary, Ingrid, Sands, Kathy, Sinha, Tapati, Schofield, Julia, Shipman, Alexa, Siebert, Stefan, Stefanescu, Simina, Sundararaj, Kavitha, Taghipour, Kathy, Taylor, Michelle, Thomson, Michelle, Topliffe, Joanne, Verdolini, Roberto, Wachsmuth, Rachel, Wade, Martin, Wahie, Shymal, Walsh, Sarah, Wilcox, Louise, Williamson, Diane, Wright, Andrew, Al-Janabi, Ali, Martin, Paul, Khan, Adnan R., Foulkes, Amy C., Smith, Catherine H., Griffiths, Christopher E.M., Morris, Andrew P., Eyre, Steve, and Warren, Richard B.

Published
2023
Full Text
View/download PDF

13. Psoriasis

Author

George, Christina, Bewley, Anthony, Bewley, Anthony, editor, Lepping, Peter, editor, and Taylor, Ruth, editor

Published
2021
Full Text
View/download PDF

14. Nodular Prurigo

Author

Bewley, Anthony, Barlow, Richard, Bewley, Anthony, editor, Lepping, Peter, editor, and Taylor, Ruth, editor

Published
2021
Full Text
View/download PDF

18. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis

Author

Evans, Ian, Murphy, Ruth, McPherson, Tess, Kleyn, Elise, Laws, Philip, Becher, Gabrielle, Bewley, Anthony, Rashid, Amir, Alabas, Oras, Morrison, Simon, Ahmed, Shehnaz, Pearson, Eleanor, Richards, Josh, Mackenzie, Teena, Kirby, Brian, Burden, David, Lawson, Linda, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Aldoori, Nadia, Ali, Mahmud, Anstey, Alex, Antony, Fiona, Archer, Charles, August, Suzanna, Balasubramaniam, Periasamy, Baxter, Kay, Bonsall, Alexandra, Brown, Victoria, Burova, Katya, Butt, Aamir, Caswell, Mel, Cliff, Sandeep, Costache, Mihaela, Darne, Sharmela, Davies, Emily, DeGiovanni, Claudia, Desai, Trupti, DeSilva, Bernadette, Diba, Victoria, Domanne, Eva, Dymond, Harvey, Fahy, Caoimhe, Ferguson, Leila, Gkini, Maria-Angeliki, Godwin, Alison, Hammonds, Fiona, Johnson, Sarah, Joseph, Teresa, Kalavala, Manju, Khorshid, Mohsen, Labinoti, Liberta, Lawson, Nicole, Layton, Alison, Lees, Tara, Levell, Nick, Lewis, Helen, Lyon, Calum, McBride, Sandy, McCormack, Sally, McKenna, Kevin, Mellor, Serap, Norris, Paul, Popli, Urvi, Perera, Gay, Ponnambath, Nabil, Ramsay, Helen, Ranasinghe, Aruni, Reeken, Saskia, Rose, Rebecca, Rotarescu, Rada, Salvary, Ingrid, Sands, Kathy, Sinha, Tapati, Stefanescu, Simina, Sundararaj, Kavitha, Taghipour, Kathy, Taylor, Michelle, Thomson, Michelle, Topliffe, Joanne, Verdolini, Roberto, Wachsmuth, Rachel, Wade, Martin, Wahie, Shyamal, Walsh, Sarah, Walton, Shernaz, Wilcox, Louise, Wright, Andrew, Douroudis, Konstantinos, Ramessur, Ravi, Barbosa, Ines A., Baudry, David, Duckworth, Michael, Angit, Caroline, Capon, Francesca, Chung, Raymond, Curtis, Charles J., Di Meglio, Paola, Goulding, Jonathan M.R., Griffiths, Christopher E.M., Lee, Sang Hyuck, Mahil, Satveer K., Parslew, Richard, Reynolds, Nick J., Shipman, Alexa R., Warren, Richard B., Yiu, Zenas Z.N., Simpson, Michael A., Barker, Jonathan N., Dand, Nick, and Smith, Catherine H.

Published
2022
Full Text
View/download PDF

24. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions:Results from a Survey in Five European Countries

Author

Vañó-Galván, Sergio, Egeberg, Alexander, Piraccini, Bianca Maria, Marwaha, Simran, Reed, Catherine, Johansson, Erin, Durand, Frederick, Bewley, Anthony, Vañó-Galván, Sergio, Egeberg, Alexander, Piraccini, Bianca Maria, Marwaha, Simran, Reed, Catherine, Johansson, Erin, Durand, Frederick, and Bewley, Anthony

Abstract

Introduction Alopecia areata (AA) is an autoimmune condition that causes non-scarring hair loss and can impose a high psychosocial burden on patients. The presence of comorbid conditions may impact the management of AA in clinical practice. This analysis aims to describe disease characteristics and management of AA in patients with concomitant atopic, autoimmune, and psychiatric comorbid conditions. Methods Data were collected from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians and their adult patients with AA conducted in France, Germany, Italy, Spain, and the UK between October 2021 and June 2022. Patients’ disease severity was based on physician’s definition. Physician-reported data on demographics, AA clinical characteristics, comorbid conditions, and information related to AA therapies were analyzed. Analyses were descriptive. Results Overall, 239 dermatologists provided data for 2083 patients, of which 558 patients (27%) had at least one atopic, autoimmune, or psychiatric comorbid conditions. The most common comorbid conditions were atopic dermatitis, autoimmune thyroid disease, and anxiety. The mean (standard deviation) patient age for the three comorbidity groups was 37.6 years (12.1) and 56% of the patients were women (n = 313). In the three comorbidity groups, 51%, 50%, and 55% of patients with atopic, autoimmune, and psychiatric comorbidities had severe AA with disease progression reported as worsening in 30%, 28%, and 30%, respectively, whereas in the group with no comorbidities, 37% were described as having severe AA and 21% getting worse. Scalp hair loss was the primary sign reported across the three groups of comorbid conditions (atopic, 91%; autoimmune, 91%; psychiatric, 88%). Patients with preselected comorbidities presented more frequently AA-related signs and symptoms beyond scalp hair loss than patients without comorbid conditions. These patients were also more likely to receive topic, Introduction: Alopecia areata (AA) is an autoimmune condition that causes non-scarring hair loss and can impose a high psychosocial burden on patients. The presence of comorbid conditions may impact the management of AA in clinical practice. This analysis aims to describe disease characteristics and management of AA in patients with concomitant atopic, autoimmune, and psychiatric comorbid conditions. Methods: Data were collected from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians and their adult patients with AA conducted in France, Germany, Italy, Spain, and the UK between October 2021 and June 2022. Patients’ disease severity was based on physician’s definition. Physician-reported data on demographics, AA clinical characteristics, comorbid conditions, and information related to AA therapies were analyzed. Analyses were descriptive. Results: Overall, 239 dermatologists provided data for 2083 patients, of which 558 patients (27%) had at least one atopic, autoimmune, or psychiatric comorbid conditions. The most common comorbid conditions were atopic dermatitis, autoimmune thyroid disease, and anxiety. The mean (standard deviation) patient age for the three comorbidity groups was 37.6 years (12.1) and 56% of the patients were women (n = 313). In the three comorbidity groups, 51%, 50%, and 55% of patients with atopic, autoimmune, and psychiatric comorbidities had severe AA with disease progression reported as worsening in 30%, 28%, and 30%, respectively, whereas in the group with no comorbidities, 37% were described as having severe AA and 21% getting worse. Scalp hair loss was the primary sign reported across the three groups of comorbid conditions (atopic, 91%; autoimmune, 91%; psychiatric, 88%). Patients with preselected comorbidities presented more frequently AA-related signs and symptoms beyond scalp hair loss than patients without comorbid conditions. These patients were also more likely to receive topical calcineurin inhibitor

Published
2024

25. Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey

Author

Bewley,Anthony, Figueras-Nart,Ignasi, Zhang,Jainzhong, Guerreiro,Mariana, Tietz,Nicole, Chtourou,Sami, Durand,Frederick, Blume-Peytavi,Ulrike, Bewley,Anthony, Figueras-Nart,Ignasi, Zhang,Jainzhong, Guerreiro,Mariana, Tietz,Nicole, Chtourou,Sami, Durand,Frederick, and Blume-Peytavi,Ulrike

Abstract

Anthony Bewley,1 Ignasi Figueras-Nart,2 Jainzhong Zhang,3 Mariana Guerreiro,4 Nicole Tietz,4 Sami Chtourou,4 Frederick Durand,4 Ulrike Blume-Peytavi5 1Department of Dermatology, The Royal London Hospital & Queen Mary University, London, UK; 2Department of Dermatology, University Hospital de Bellvitge, Barcelona, Spain; 3Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China; 4Eli Lilly and Company Ltd, Indianapolis, IN, USA; 5Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, GermanyCorrespondence: Anthony Bewley, Department of Dermatology, The Royal London Hospital & Queen Mary University, London, UK, Tel +44 020 7767 3200, Email anthony.bewley@nhs.netPurpose: Alopecia areata (AA) is an autoimmune disease characterized by hair loss that has significant psychosocial implications. This study aims to describe the patient-reported burden of severe AA, coping mechanism and information needs using data from the multinational AA Patient Satisfaction and Unmet Need Survey.Patients and Methods: Participants with current or previous ≥ 50% scalp hair loss (n = 747) were recruited from 11 countries and completed a web-based survey that assessed demographics, clinical characteristics, disease burden and psychosocial impact. Data were stratified according to sex, current age, disease duration and current severity of scalp hair loss.Results: The mean (SD) age of participants was 43.8 (7.1) years, 55.3% were women, and 63.5% reported AA symptoms within 6 months of diagnosis. Most participants had black or brown hair (88.4%), reported a disease duration of 2 years or more (75.6%) and had current scalp hair loss of ≥ 50% (87.4%). Severe hair loss also extended to eyebrow (46.9%), eyelash (48.7), beard (61.5%) and body hair (73.2%). Participants commonly reported comorbidities such as anx

Published
2024

28. 542 - Validation of the skin pain numerical rating scale of the Pruritus and Symptoms Assessment for Atopic Dermatitis for adults and adolescents with moderate-to-severe atopic dermatitis

Author

Silverberg, Jonathan I, primary, Ständer, Sonja, additional, Kim, Brian S, additional, Bewley, Anthony, additional, Misery, Laurent, additional, Vestergaard, Christian, additional, Gooderham, Melinda J, additional, Bushmakin, Andrew G, additional, Cappelleri, Joseph C, additional, Güler, Erman, additional, Alderfer, Justine, additional, Watkins, Melissa, additional, Selfridge, Andrew, additional, and Myers, Daniela E, additional

Published
2024
Full Text
View/download PDF

29. Classification of psychodermatological disorders: Proposal of a new international classification

Author

Ferreira, Bárbara Roque, primary, Vulink, Nienke, additional, Mostaghimi, Ladan, additional, Jafferany, Mohammad, additional, Balieva, Flora, additional, Gieler, Uwe, additional, Poot, Françoise, additional, Reich, Adam, additional, Romanov, Dmitry, additional, Szepietowski, Jacek C., additional, Tomas‐Aragones, Lucia, additional, Campos, Ricardo, additional, Tausk, Francisco, additional, Zipser, Marie, additional, Bewley, Anthony, additional, and Misery, Laurent, additional

Published
2023
Full Text
View/download PDF

30. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

Author

Thyssen, Jacob P., primary, Bewley, Anthony, additional, Ständer, Sonja, additional, Castro, Carla, additional, Misery, Laurent, additional, Kim, Brian S., additional, Biswas, Pinaki, additional, Chan, Gary, additional, Myers, Daniela E., additional, Watkins, Melissa, additional, Alderfer, Justine, additional, Güler, Erman, additional, and Silverberg, Jonathan I., additional

Published
2023
Full Text
View/download PDF

31. A retrospective review of pregnancies in our psoriasis biologic cohort.

Author

Wolfe, Charlotte, Kennard, Benjamin, Bewley, Anthony, and Mehrtens, Sarah

Subjects
ABORTION, PREGNANCY outcomes, MATERNAL age, INFLAMMATORY bowel diseases, OBSTETRICS, BIOTHERAPY, NEONATAL sepsis
Abstract

This article discusses the safety of biologic medications for pregnant women with psoriasis. The British Association of Dermatologists advises that most pregnancies in women taking biologic therapy have successful outcomes, but there is limited evidence on the risks of fetal abnormalities. The study reviewed the outcomes of 15 pregnancies in a biologic cohort over a 10-year period. The results showed that the majority of pregnancies were successful, resulting in healthy children with no fetal anomalies. The study suggests that biologic therapy for psoriasis is generally safe in pregnancy, but more research is needed on the risk of infection and other outcomes in infants. [Extracted from the article]

Published
2024
Full Text
View/download PDF

33. Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement

Author

Dirr, McKenzie A., Ahmed, Areeba, Schlessinger, Daniel I., Haq, Misha, Shi, Victoria, Koza, Eric, Ma, Melissa, Christensen, Rachel E., Ibrahim, Sarah A., Schmitt, Jochen, Johannsen, Lena, Asai, Yuka, Baldwin, Hilary E., Berardesca, Enzo, Berman, Brian, Vieira, Ana Carolina, Chien, Anna L., Cohen, David E., Del Rosso, James Q., Dosal, Jacquelyn, Drake, Lynn A., Feldman, Steven R., Fleischer, Alan B., Friedman, Adam, Graber, Emmy, Harper, Julie C., Helfrich, Yolanda R., Jemec, Gregor B., Johnson, Sandra M., Katta, Rajani, Lio, Peter, Maier, Lisa E., Martin, George, Nagler, Arielle R., Neuhaus, Isaac M., Palamar, Melis, Parish, Lawrence C., Rosen, Theodore, Shumack, Stephen P., Solomon, James A., Tanghetti, Emil A., Webster, Guy F., Weinkle, Allison, Weiss, Jonathan S., Wladis, Edward J., Maher, Ian A., Sobanko, Joseph F., Cartee, Todd V., Cahn, Brian A., Alam, Murad, Kang, Bianca Y., Iyengar, Sanjana, Anvery, Noor, Alpsoy, Erkan, Bewley, Anthony, Dessinioti, Clio, Egeberg, Alexander, Engin, Burhan, Gollnick, Harald P. M., Ioannides, Dimitrios, Kim, Hei Sung, Lazaridou, Elizabeth, Li, Ji, Lim, Hester Gail, Micali, Giuseppe, de Oliveira, Clivia Maria Moraes, Noguera-Morel, Lucero, Parodi, Aurora, Reinholz, Markus, Suh, Dae Hun, Sun, Qiuning, van Zuuren, Esther J, Wollina, Uwe, Zhou, Youwen, Zip, Catherine, Poon, Emily, and Pearlman, Ross

Abstract

IMPORTANCE: Inconsistent reporting of outcomes in clinical trials of rosacea is impeding and likely preventing accurate data pooling and meta-analyses. There is a need for standardization of outcomes assessed during intervention trials of rosacea. OBJECTIVE: To develop a rosacea core outcome set (COS) based on key domains that are globally relevant and applicable to all demographic groups to be used as a minimum list of outcomes for reporting by rosacea clinical trials, and when appropriate, in clinical practice. EVIDENCE REVIEW: A systematic literature review of rosacea clinical trials was conducted. Discrete outcomes were extracted and augmented through discussions and focus groups with key stakeholders. The initial list of 192 outcomes was refined to identify 50 unique outcomes that were rated through the Delphi process Round 1 by 88 panelists (63 physicians from 17 countries and 25 patients with rosacea in the US) on 9-point Likert scale. Based on feedback, an additional 11 outcomes were added in Round 2. Outcomes deemed to be critical for inclusion (rated 7-9 by ≥70% of both groups) were discussed in consensus meetings. The outcomes deemed to be most important for inclusion by at least 85% of the participants were incorporated into the final core domain set. FINDINGS: The Delphi process and consensus-building meetings identified a final core set of 8 domains for rosacea clinical trials: ocular signs and symptoms; skin signs of disease; skin symptoms; overall severity; patient satisfaction; quality of life; degree of improvement; and presence and severity of treatment-related adverse events. Recommendations were also made for application in the clinical setting. CONCLUSIONS AND RELEVANCE: This core domain set for rosacea research is now available; its adoption by researchers may improve the usefulness of future trials of rosacea therapies by enabling meta-analyses and other comparisons across studies. This core domain set may also be useful in clinical practice.

Published
2024
Full Text
View/download PDF

34. Classification of psychodermatological disorders: Proposal of a new international classification.

Author

Ferreira, Bárbara Roque, Vulink, Nienke, Mostaghimi, Ladan, Jafferany, Mohammad, Balieva, Flora, Gieler, Uwe, Poot, Françoise, Reich, Adam, Romanov, Dmitry, Szepietowski, Jacek C., Tomas‐Aragones, Lucia, Campos, Ricardo, Tausk, Francisco, Zipser, Marie, Bewley, Anthony, and Misery, Laurent

Abstract

Introduction: Several classifications of psychodermatology disorders have been proposed, with most of them based on two to four main disorder category groups. However, there is, to date, no classification that has resulted from a consensus established by psychodermatology experts. The DSM‐5‐TR (Diagnostic and statistical manual of mental disorders (5th ed.), Text Revision) and the ICD‐11 (International classification of diseases (11th revision)) also do not provide a systematized approach of psychodermatology disorders. Taking into consideration that classifications are a key pillar for a comprehensive approach to the pathologies of each branch of medicine, the proposal of a classification in psychodermatology appeared as a central need for the recognition of psychodermatological disorders, in an attempt to improve their recognition and, in that sense, to find a common language for the development of this subspecialty that crosses dermatology and psychiatry. Methods: Previously published classifications in psychodermatology were critically reviewed and discussed by expert opinion from an international multidisciplinary panel of 16 experts in psychodermatology and a new classification system is proposed, considering classical concepts in general dermatology and psychopathology. Results: Two main categories of disorders are presented (a main group related to primary mental health disorders and another main group related to primary skin disorders), which are subsequently subdivided into subgroups considering pathophysiological and phenomenological similarities, including key aspects of dermatological examination, namely the presence of visible skin lesions (primary and secondary skin lesions) and psychopathological correlates. Conclusion: This new classification aims to unify previous classifications, systematize the disorders that belong to psychodermatology and highlight their tenuous boundaries, to improve their management. It has been built and approved by the Psychodermatology Task Force of the European Academy of Dermatology and Venereology (EADV), the European Society for Dermatology and Psychiatry (ESDaP) and the Association for Psychoneurocutaneous Medicine of North America (APMNA). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.

Author

Thyssen, Jacob P., Bewley, Anthony, Ständer, Sonja, Castro, Carla, Misery, Laurent, Kim, Brian S., Biswas, Pinaki, Chan, Gary, Myers, Daniela E., Watkins, Melissa, Alderfer, Justine, Güler, Erman, and Silverberg, Jonathan I.

Subjects
ATOPIC dermatitis, QUALITY of life, ADULTS, TEENAGERS, ITCHING, PAIN threshold, ECZEMA
Abstract

Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. Objectives: The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD. Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item ("How painful was your skin over the past 24 h?") on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children's Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed-effects repeated measures modeling. Results: A total of 1,822 patients (monotherapy pool, n = 942; JADE COMPARE, n = 595; and JADE TEEN, n = 285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs. 12%; week 12), JADE COMPARE (72% and 52% vs. 26%; week 16), and JADE TEEN (51% and 60% vs. 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score <2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations. Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis

Author

Armstrong, April, primary, Ghoreschi, Kamran, additional, Rosmarin, David, additional, Schlesinger, Todd, additional, Irvine, Alan, additional, Bewley, Anthony, additional, Casillas, Marta, additional, Gallo, Gaia, additional, Ding, Yuxin, additional, Xu, Chenjia, additional, Pau-Charles, Ignasi, additional, and Simpson, Eric, additional

Published
2023
Full Text
View/download PDF

38. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials

Author

Piraccini, Bianca M., primary, Ohyama, Manabu, additional, Craiglow, Brittany, additional, Bewley, Anthony, additional, Ding, Yuxin, additional, Chen, Yun‐Fei, additional, Dutronc, Yves, additional, Pierce, Evangeline, additional, Durand, Frederick, additional, and Mostaghimi, Arash, additional

Published
2023
Full Text
View/download PDF

41. Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nurses

Author

van Ee, Ilse, primary, Deprez, Elfie, additional, Egeberg, Alexander, additional, Conrad, Curdin, additional, Corazza, Valeria, additional, Donati, Ludovica, additional, Lambert, Jo, additional, Lăpădatu, Rozalina, additional, Meyer, Anette, additional, Paul, Carle, additional, Penzer‐Hick, Rebecca, additional, Stephen, Karen, additional, van der Zon, Jim, additional, and Bewley, Anthony, additional

Published
2023
Full Text
View/download PDF

43. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics

Author

Al-Janabi, Ali, primary, Martin, Paul, additional, Khan, Adnan R., additional, Foulkes, Amy C., additional, Smith, Catherine H., additional, Griffiths, Christopher E.M., additional, Morris, Andrew P., additional, Eyre, Steve, additional, Warren, Richard B., additional, Ahmed, Shehnaz, additional, Alabas, Oras, additional, Barker, Jonathan, additional, Becher, Gabrielle, additional, Bewley, Anthony, additional, Evans, Ian, additional, Hampton, Philip, additional, Kirby, Brian, additional, Kleyn, Elise, additional, Laws, Philip, additional, Lawson, Linda, additional, Mackenzie, Teena, additional, McElhone, Kathleen, additional, McPherson, Tess, additional, Morrison, Simon, additional, Owen, Caroline, additional, Pearson, Eleanor, additional, Rashid, Amir, additional, Reynolds, Nick, additional, Strangfeld, Anja, additional, Walton, Shernaz, additional, Yiu, Zenas, additional, Gupta, Girish, additional, Strangfeld (chair), Anja, additional, Weller, Richard, additional, Zietemann, Vera, additional, Aldoori, Nadia, additional, Ali, Mahmud, additional, Al-Rusan, Ahmed, additional, Angit, Caroline, additional, Anstey, Alex, additional, Antony, Fiona, additional, Archer, Charles, additional, August, Suzanna, additional, Balasubramaniam, Periasamy, additional, Baudry, David, additional, Baxter, Kay, additional, Bonsall, Alexandra, additional, Brown, Sara, additional, Brown, Victoria, additional, Burden, David, additional, Burova, Ekaterina, additional, Butt, Aamir, additional, Caswell, Mel, additional, Chapman, Anna, additional, Cliff, Sandeep, additional, Costache, Mihaela, additional, Darne, Sharmela, additional, DeGiovanni, Claudia, additional, Desai, Trupti, additional, Diba, Victoria, additional, Domanne, Eva, additional, Duckworth, Michael, additional, Dymond, Harvey, additional, Fahy, Caoimhe, additional, Farwer, Susanne, additional, Ferguson, Leila, additional, Gkini, Maria-Angeliki, additional, Godwin, Alison, additional, Goulding, Jon, additional, Hammonds, Fiona, additional, Haque, Shaheen, additional, Higgins, Caroline, additional, Hood, Sue, additional, Joseph, Teresa, additional, Johnson, Sarah, additional, Kalavala, Manju, additional, Khorshid, Mohsen, additional, Labinoti, Liberta, additional, Lamb, Ruth, additional, Lawson, Nicole, additional, Layton, Alison, additional, Lees, Tara, additional, Levell, Nick, additional, Lewis, Helen, additional, Lovell, Chris, additional, Lyon, Calum, additional, McAteer, Helen, additional, McBride, Sandy, additional, McCormack, Sally, additional, McKenna, Kevin, additional, Mellor, Serap, additional, Meredith, Fiona, additional, Murphy, Ruth, additional, Norris, Paul, additional, Parslew, Richard, additional, Perera, Gay, additional, Ponnambath, Nabil, additional, Popli, Urvi, additional, Powell, James, additional, Ramesh, Raakhee, additional, Ramsay, Helen, additional, Ranasinghe, Aruni, additional, Reeken, Saskia, additional, Rose, Rebecca, additional, Rotarescu, Rada, additional, Salvary, Ingrid, additional, Sands, Kathy, additional, Sinha, Tapati, additional, Schofield, Julia, additional, Shipman, Alexa, additional, Siebert, Stefan, additional, Stefanescu, Simina, additional, Sundararaj, Kavitha, additional, Taghipour, Kathy, additional, Taylor, Michelle, additional, Thomson, Michelle, additional, Topliffe, Joanne, additional, Verdolini, Roberto, additional, Wachsmuth, Rachel, additional, Wade, Martin, additional, Wahie, Shymal, additional, Walsh, Sarah, additional, Wilcox, Louise, additional, Williamson, Diane, additional, and Wright, Andrew, additional

Published
2023
Full Text
View/download PDF

45. Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nurses.

Author

van Ee, Ilse, Deprez, Elfie, Egeberg, Alexander, Conrad, Curdin, Corazza, Valeria, Donati, Ludovica, Lambert, Jo, Lăpădatu, Rozalina, Meyer, Anette, Paul, Carle, Penzer‐Hick, Rebecca, Stephen, Karen, van der Zon, Jim, and Bewley, Anthony

Subjects
DELPHI method, PATIENTS' attitudes, PSORIASIS, MEDICAL personnel, PHYSICIANS, DERMATOLOGISTS
Abstract

This article discusses the importance of considering patients' perspectives in the treatment of psoriasis, a chronic skin disease that can significantly impact quality of life. The study conducted a Delphi consensus involving psoriasis patients, physicians, and nurses to determine the definition of freedom from disease in psoriasis. The results showed that while there was a high level of consensus among all groups, there were some differences in the perceived importance of various aspects of freedom from disease. For example, physicians placed greater importance on the management of clinical symptoms, while patients were more concerned about the cost of treatments. The study also found that patients with milder psoriasis placed greater importance on psychosocial elements and healthcare team support, while patients with more severe psoriasis were less concerned with the cost of treatment. Additionally, females placed greater importance on psychosocial elements, such as worrying about other people's reactions to their skin. The findings suggest the need for personalized treatment plans and shared decision-making between patients and healthcare professionals. However, it is important to note that the study has limitations, such as the potential lack of representativeness in certain groups. [Extracted from the article]

Published
2024
Full Text
View/download PDF

46. White paper on psychodermatology in Europe: A position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP).

Author

Misery, Laurent, Schut, Christina, Balieva, Flora, Bobko, Svetlana, Reich, Adam, Sampogna, Francesca, Altunay, Ilknur, Dalgard, Florence, Gieler, Uwe, Kupfer, Jörg, Lvov, Andrey, Poot, Françoise, Szepietowski, Jacek C., Tomas‐Aragones, Lucia, Vulink, Nienke, Zalewska‐Janowska, Anna, and Bewley, Anthony

Subjects
TASK forces, DERMATOLOGY, PSYCHIATRY, DERMATOLOGISTS
Abstract

Psychodermatology is a subspecialty of dermatology that is of increasing interest to dermatologists and patients. The case for the provision of at least regional psychodermatology services across Europe is robust. Psychodermatology services have been shown to have better, quicker and more cost‐efficient clinical outcomes for patients with psychodermatological conditions. Despite this, psychodermatology services are not uniformly available across Europe. In fact many countries have yet to establish dedicated psychodermatology services. In other countries psychodermatology services are in development. Even in countries where psychodermatolgy units have been established, the services are not available across the whole country. This is especially true for the provision of paediatric psychodermatology services. Also whilst most states across Europe are keen to develop psychodermatology services, the rate at which this development is being implemented is very slow. Our paper maps the current provision of psychodermatology services across Europe and indicates that there is still very much more work to be done in order to develop the comprehensive psychodermatology services across Europe, which are so crucial for our patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis

Author

Paller, Amy S., primary, Flohr, Carsten, additional, Cork, Michael, additional, Bewley, Anthony, additional, Blauvelt, Andrew, additional, Hong, H. Chih-ho, additional, Imafuku, Shinichi, additional, Schuttelaar, Marie L. A., additional, Simpson, Eric L., additional, Soong, Weily, additional, Arlert, Petra, additional, Lophaven, Katja Wendicke, additional, Kurbasic, Azra, additional, Soldbro, Lise, additional, Vest, Natacha Strange, additional, and Wollenberg, Andreas, additional

Published
2023
Full Text
View/download PDF

50. Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis

Author

Thyssen, Jacob P., primary, Bewley, Anthony, additional, Ständer, Sonja, additional, Castro, Carla, additional, Misery, Laurent, additional, Kim, Brian S., additional, Biswas, Pinaki, additional, Chan, Gary L., additional, Myers, Daniela E., additional, Watkins, Melissa, additional, Alderfer, Justine, additional, Güler, Erman, additional, and Silverberg, Jonathan I., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results